肿瘤细胞治疗研究
英文原题：Case Report: Active tuberculosis infection in CAR T-cell recipients post CAR T-cell therapy: a retrospective case series.
Case Report: Active tuberculosis infection in CAR T-cell recipients post CAR T-cell therapy: a retrospective case series.
我们的研究提供了首例CD19/CD22靶向CAR T细胞治疗后活动性TB的系列报告。
B细胞恶性肿瘤通过嵌合抗原受体（CAR）T细胞疗法已取得高缓解率。新近报道提示，新型免疫治疗肿瘤存在活动性结核（TB）风险。然而，CAR T细胞治疗后患者TB的研究有限。在本病例系列研究中，我们描述了五例在单独接受CD19/CD22靶向CAR T细胞治疗后或继自体干细胞移植（ASCT）后发生活动性TB的患者。其中一例患者在CAR T细胞治疗后30天内发生活动性TB，发热是主要表现症状；其他四例患者肺外表现常见，并在CAR T细胞治疗后30天后出现。五例患者中有四例经抗TB治疗后好转，但一例异烟肼耐药患者死于中枢神经系统TB感染。我们的研究提供了首例系列报告，描述CD19/CD22靶向CAR T细胞治疗后活动性TB。
High response rates in B-cell malignancies have been achieved with chimeric antigen receptor (CAR) T-cell therapy. Emerging reports indicate a risk of active tuberculosis (TB) with novel immunotherapy for tumors. However, studies of TB in patients post CAR T-cell therapy are limited. In this case series study, we describe five patients with active TB post CD19/CD22 target CAR T-cell therapy alone or following autologous stem cell transplantation (ASCT). One of the patients developed active TB within the first 30 days post CAR T-cell therapy, and fever was the dominant presenting symptom; extrapulmonary manifestations of active TB were common in the other four patients and manifested after the first 30 days of CAR T-cell therapy. Four of the five patients improved with anti-TB treatment, but one patient with isoniazid resistance died of central nervous system TB infection. Our study provides the first series report of active TB following CD19/CD22 target CAR T-cell therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
